Usefulness of intravenous ciprofloxacin for community-acquired pneumonia negative in Binax Now Streptococcus pneumoniae, Binax Now Legionellae, and ImmunoCard Mycoplasma antibody.

Accession number;06A0874652
Title;Usefulness of intravenous ciprofloxacin for community-acquired pneumonia negative in Binax Now Streptococcus pneumoniae, Binax Now Legionellae, and ImmunoCard Mycoplasma antibody.
Author;OKIMOTO NIRO(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   KISHIMOTO MICHIHIRO(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   KIBAYASHI TAKASHI(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   MIMURA KIMIHIRO(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   YAMATO KENJI(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   HONDA YOSHIHIRO(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   OSAKI KOHICHI(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   KURIHARA TAKEYUKI(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   ASAOKA NAOKO(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   OHBA HIDEO(Kawasaki Medical School Kawasaki Hospital, Okayama, Jpn)   
Journal Title;Med Postgrad
Journal Code:X0599A
ISSN:0285-4716
VOL.44;NO.4;PAGE.403-407(2006)
Figure&Table&Reference;TBL.6, REF.14
Pub. Country;Japan
Language;English
Abstract;Usefulness of intravenous ciprofloxacin (CPFX) for community-acquired pneumonia negative in Binax Now Streptococcus pneumoniae, Binax Now Legionellae, and ImmunoCard Mycoplasma antibody was examined. The subjects were 30 patients with moderate community-acquired pneumonia who were negative in Binax Now Streptococcus pneumoniae, Binax Now Legionellae, and ImmunoCard Mycoplasma antibody. Intravenous CPFX was administered 300mg/once, twice daily, for 3-14 days, and clinical efficacy, bacteriological efficacy, and side effect were prospectively examined. As a result, it was effective in 28 of 30 patients with effective rate of 93.3%. Bacteriologically, all the detected strains were eradicated including 4 strains of Haemophilus influenzae, each 2 of methicillin-sensitive Staphylococcus aureus and Escherichia coli, and each 1 of Klebsiella pneumoniae, and Enterobacter aerogenes. Side effects included elevation in GPT in 2 patients, elevation in GOT, Crn, and BUN in 1, elevation in GOT and .GAMMA.-GTP in 1, and elevation in BUN in 1. All of them were mild. Based on the above, it was concluded that intravenous CPFX is effective for community-acquired pneumonia which was negative in examinations on Binax Now Streptococcus pneumoniae, Binax Now Legionellae, and ImmunoCard Mycoplasma antibody. (author abst.)